Molecular Profiling Can Guide Treatment After Recurrence in Young Cancer Patients
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
Endocrine Cancer Mobile
ENDOCRINE CANCER ADVISOR
Endocrine Cancer News
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Risk of Breakthrough COVID-19 Varies by Cancer Type
The risk of breakthrough SARS-CoV-2 infections was highest for liver cancer and lowest for thyroid cancer.
Pandemic Tied to Drop in New Cancer Diagnoses
At the start of the pandemic, there was an immediate 34.3% decline in the estimated mean cancer incidence volume.
Radioiodine Provides No Benefit After Thyroidectomy in Low-Risk Thyroid Cancer
Radioiodine after thyroidectomy did not improve outcomes in patients with low-risk thyroid cancer.
Peptide Receptor Radionuclide Therapy Prolongs PFS in Enteropancreatic Neuroendocrine Tumors
When compared with chemotherapy or targeted therapy, peptide receptor radionuclide therapy significantly prolonged progression-free survival.
Exploring a Potential Link Between Children With Obesity and Thyroid Cancer
Researchers hypothesized that a rising number of thyroid cancer rates in adults with obesity in may also imply an increase in thyroid cancer rates in children.
Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer
The complete response rate was similar for patients who received selumetinib and those who received radioactive iodine alone.
Pandemic-Related Decreases in Cancer Detection Persist for Some Cancers
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
3MT Gene Signature May Predict Poor Outcomes in Neuroblastoma
Elevated urinary 3MT levels were tied to worse event-free and overall survival.
Recurrence of Papillary Thyroid Cancer Predicted by Genetic Risk Model
Analysis of messenger RNA, microRNA, and protein-encoding genes may predict the risk of papillary thyroid cancer recurrence.
Apatinib Improves PFS, OS in Radioactive Iodine-Refractory Thyroid Cancer
Apatinib improved progression-free survival regardless of baseline thyroglobulin levels.
Adding Monoclonal Antibody to Induction Could Be New Standard Care for High-Risk Neuroblastoma
Results from a phase 2 trial, if validated in a larger study, may be practice-changing, according to researchers.
¹⁷⁷Lu-Dotatate Provides ‘Clinically Relevant’ Improvement in Midgut Neuroendocrine Tumors
¹⁷⁷Lu-Dotatate improved the median overall survival by 11.7 months.
Regimen May Be Beneficial as Palliative Care for Children, Young Adults With Solid Tumors
Stable disease was observed in 51.3% of patients.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
Genomic Sequencing in Pediatric Cancer: For Every Patient at Every Relapse
More than one-third of tumors sequenced carried a high mutation burden.
Nomogram Could Aid Clinical Decision-Making for Gastroenteropancreatic Neuroendocrine Tumors
The nomogram proved more accurate than TNM staging for predicting 3-year and 5-year overall survival.
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
‘Practice-Changing’ Results With Sunitinib in Malignant Pheochromocytoma and Paraganglioma
The 12-month progression-free survival rate was 35.9% with sunitinib and 18.9% with placebo.
Cabometyx Approved for Radioactive Iodine-Refractory Differentiated Thyroid Cancer
The approval was based on data from the phase 3 COSMIC-311 study.
Multifocality Appears to Increase Risk of Recurrence in Papillary Thyroid Carcinoma
The risk of recurrence varied by patient age, tumor size, and number of foci.
Vorinostat Plus MIBG Proves More Effective Than Other MIBG Regimens in Relapsed or Refractory Neuroblastoma
Response rates were highest with MIBG plus vorinostat.
‘Excellent’ Outcomes and Room for Improvement in Pediatric Adrenocortical Carcinoma
Patients with stage II or IV disease did not fare as well as patients with stage I or III disease.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...